Clinical-stage biotechnology company Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA) announced on Monday that it has received clearance from the U.S. FDA for its Investigational New Drug (IND) application to begin a Phase 1 clinical trial of IPH4502, a novel Antibody Drug Conjugate (ADC) targeting Nectin-4, a protein overexpressed in various solid tumours.

The upcoming trial will evaluate the safety, tolerability and preliminary efficacy of IPH4502 in cancers such as urothelial carcinoma, non-small cell lung, breast, ovarian and colorectal cancers.

IPH4502 is a topoisomerase I inhibitor ADC conjugated to exatecan, aiming to deliver targeted anti-tumour activity with limited impact on normal tissues. The Phase 1 study will be conducted in two parts: dose escalation and dose optimisation.

Innate Pharma continues to focus on leveraging its proprietary ANKET platform and expertise in immunotherapy to develop innovative treatments for cancer, with collaborations involving partners like AstraZeneca and Sanofi.